PipelineReview.com17h
AbbVie Announces Positive Topline Results from Phase 3 TEMPO-1 Trial Evaluating Tavapadon as a Monotherapy for Parkinson’s Disease
NORTH CHICAGO, IL, USA I6, 2024 I AbbVie (NYSE: ABBV) today announced positive topline results from its pivotal Phase 3 TEMPO-1 trial for ...
PipelineReview.com17h
Repair Biotechnologies and Genevant Sciences to Collaborate to Develop mRNA-LNP Therapy with First-in-Class Potential to Turn Back Atherosclerosis
SYRACUSE, NY, USA; VANCOUVER, Canada; and BASEL, Switzerland I6, 2024 I Repair Biotechnologies, a biotechnology company developing first-in-class ...
PipelineReview.com17h
ReCode Therapeutics Doses First Patient in Phase 1b Clinical Study of RCT2100 for the Treatment of Cystic Fibrosis
Phase 1b study will evaluate the safety and tolerability of multiple ascending doses of RCT2100 in people with cystic fibrosis – ...
PipelineReview.com15h
Sage Therapeutics Announces Discontinuation of the Collaboration with Biogen on the SAGE-324 Program
Sage and Biogen will continue to partner on ZURZUVAE®, the first and only FDA-approved oral treatment for women with postpartum depression CAMBRIDGE, MA, USA I September 26, 2024 I Sage Therapeutics, ...